TAKE A CLOSER LOOK AT THE BENEFITS OF OMIDRIA


FIRST AND ONLY FDA-APPROVED PRODUCT OF ITS KIND FOR CATARACT SURGERY1


MIOSIS PREVENTION AND POST-OP OCULAR PAIN REDUCTION IN ONE1


CONTINUOUS THERAPEUTIC EFFECT THROUGHOUT SURGERY1


PROVEN 4-6 TIMES BETTER THAN INTRACAMERAL PHENYLEPHRINE OR KETOROLAC ALONE2,


*


®


REIMBURSED SEPARATELY FROM BUNDLED PAYMENT UNTIL DECEMBER 31, 20173,4


FULLY REIMBURSABLE ACROSS ALL PAYER TYPES2,4,5


AFTER BUNDLING, POSITIVE EFFECT ON FACILITY FEES4


NO EFFECT ON PHYSICIAN FEES; PASS-THROUGH PAYMENTS HAVE NO EFFECT ON HEALTHCARE SYSTEM4


IMPORTANT SAFETY INFORMATION OMIDRIA®


INDICATIONS AND USAGE (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution prior to intraocular use.


OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.


Systemic exposure of phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-infl ammatories (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation, increased intraocular pressure, and anterior chamber infl ammation.


Use of OMIDRIA in children has not been established.


You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.


OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.


* Randomized, double-masked trial using a 4-arm factorial design to show that OMIDRIA is superior to either agent alone. Post hoc analysis of pupil diameter < 6mm at any time during the procedure.2


Reimbursement information is based on Omeros data on fi le. Omeros does not guarantee reimbursement for any particular patient. Contact 1-844-OMEROS1 (1-844-663-7671) for more information about how to submit for OMIDRIA reimbursement.


References: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2015. 2. Omeros data on fi le. 3. Department of Health and Human Services. Centers for Medicare and Medicaid Services. MLN Matters. Number MM9014. 2014:1-19. 4. Federal Register, April 7, 2000, 65 FR. 5. Kaiser Family Foundation analysis of the CMS Medicare Current Benefi ciary Survey Cost and Use File, 2010.


OMEROS® , the OMEROS logo® , OMIDRIA® , and the OMIDRIA logo®


are registered trademarks of Omeros Corporation. © Omeros Corporation 2015, all rights reserved. 2015-196.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42